<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Cheminform</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Cheminform</journal-id>
    <journal-title-group>
      <journal-title>Journal of Cheminformatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-2946</issn>
    <publisher>
      <publisher-name>Springer International Publishing</publisher-name>
      <publisher-loc>Cham</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">5745209</article-id>
    <article-id pub-id-type="publisher-id">255</article-id>
    <article-id pub-id-type="doi">10.1186/s13321-017-0255-6</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Methodology</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Systematic exploration of multiple drug binding sites</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Bálint</surname>
          <given-names>Mónika</given-names>
        </name>
        <address>
          <email>monibalint18@gmail.com</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jeszenői</surname>
          <given-names>Norbert</given-names>
        </name>
        <address>
          <email>jeszenoi.norbert@gmail.com</email>
        </address>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Horváth</surname>
          <given-names>István</given-names>
        </name>
        <address>
          <email>horvathi@gmx.de</email>
        </address>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>van der Spoel</surname>
          <given-names>David</given-names>
        </name>
        <address>
          <email>david.vanderspoel@icm.uu.se</email>
        </address>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8013-971X</contrib-id>
        <name>
          <surname>Hetényi</surname>
          <given-names>Csaba</given-names>
        </name>
        <address>
          <email>csabahete@yahoo.com</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0663 9479</institution-id><institution-id institution-id-type="GRID">grid.9679.1</institution-id><institution>Department of Pharmacology and Pharmacotherapy, </institution><institution>Medical School, University of Pécs, </institution></institution-wrap>Szigeti út 12, Pécs, 7624 Hungary </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2294 6276</institution-id><institution-id institution-id-type="GRID">grid.5591.8</institution-id><institution>Department of Biochemistry, </institution><institution>Eötvös Loránd University, </institution></institution-wrap>Pázmány Péter sétány 1/C, Budapest, 1117 Hungary </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0663 9479</institution-id><institution-id institution-id-type="GRID">grid.9679.1</institution-id><institution>MTA NAP-B Molecular Neuroendocrinology Group, Institute of Physiology, Szentágothai Research Center, Center for Neuroscience, </institution><institution>University of Pécs, </institution></institution-wrap>Szigeti út 12, Pecs, 7624 Hungary </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1016 9625</institution-id><institution-id institution-id-type="GRID">grid.9008.1</institution-id><institution>Chemistry Doctoral School, </institution><institution>University of Szeged, </institution></institution-wrap>Dugonics tér 13, Szeged, 6720 Hungary </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Uppsala Center for Computational Chemistry, Science for Life Laboratory, Department of Cell and Molecular Biology, </institution><institution>University of Uppsala, </institution></institution-wrap>Box 596, 75124 Uppsala, Sweden </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>28</day>
      <month>12</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>28</day>
      <month>12</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2017</year>
    </pub-date>
    <volume>9</volume>
    <elocation-id>65</elocation-id>
    <history>
      <date date-type="received">
        <day>2</day>
        <month>8</month>
        <year>2017</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>12</month>
        <year>2017</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2017</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Targets with multiple (prerequisite or allosteric) binding sites have an increasing importance in drug design. Experimental determination of atomic resolution structures of ligands weakly bound to multiple binding sites is often challenging. Blind docking has been widely used for fast mapping of the entire target surface for multiple binding sites. Reliability of blind docking is limited by approximations of hydration models, simplified handling of molecular flexibility, and imperfect search algorithms.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par2">To overcome such limitations, the present study introduces Wrap ‘n’ Shake (WnS), an atomic resolution method that systematically “wraps” the entire target into a monolayer of ligand molecules. Functional binding sites are extracted by a rapid molecular dynamics shaker. WnS is tested on biologically important systems such as mitogen-activated protein, tyrosine-protein kinases, key players of cellular signaling, and farnesyl pyrophosphate synthase, a target of antitumor agents.<graphic position="anchor" xlink:href="13321_2017_255_Figa_HTML" id="MO1"/>
</p>
      </sec>
      <sec>
        <title>Electronic supplementary material</title>
        <p>The online version of this article (10.1186/s13321-017-0255-6) contains supplementary material, which is available to authorized users.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Peptide</kwd>
      <kwd>Search</kwd>
      <kwd>Pocket</kwd>
      <kwd>Pharmacodynamics</kwd>
      <kwd>Water</kwd>
      <kwd>Interaction</kwd>
      <kwd>Structure</kwd>
      <kwd>Complex</kwd>
      <kwd>Dissociation</kwd>
      <kwd>Flexibility</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>National Research, Development, and Innovation Office, Hungary</institution>
        </funding-source>
        <award-id>K123836</award-id>
        <award-id>K112807</award-id>
        <award-id>K120391</award-id>
        <principal-award-recipient>
          <name>
            <surname>Hetényi</surname>
            <given-names>Csaba</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group>
        <funding-source>
          <institution>University of Pécs</institution>
        </funding-source>
        <award-id>PTE ÁOK_KA/2017</award-id>
        <award-id>"Viral Pathogenesis" Talent Centre program</award-id>
        <principal-award-recipient>
          <name>
            <surname>Hetényi</surname>
            <given-names>Csaba</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group>
        <funding-source>
          <institution>Gedeon Richter Pharmaceutical Plc</institution>
        </funding-source>
        <award-id>pre-doctoral scholarship</award-id>
        <principal-award-recipient>
          <name>
            <surname>Jeszenői</surname>
            <given-names>Norbert</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2017</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1" sec-type="introduction">
    <title>Background</title>
    <p id="Par16">Molecular docking complements experimental structure determination and it has become a standard tool of drug discovery for the determination of protein–ligand complex structures [<xref ref-type="bibr" rid="CR1">1</xref>]. The technique in practice is a compromise between computational cost and accuracy. Its high speed necessitates the use of severe approximations such as (i) restriction of the search space to the surroundings of the binding site, (ii) no or inadequate explicit hydration of the ligand-target interface, (iii) partial or complete neglect of target flexibility [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR5">5</xref>] during ligand binding, (iv) and non-deterministic search algorithms [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] based on random number generation. Approximations i–iv seriously limit the applicability of docking methods for the following reasons. Restriction of the search to a primary binding site requires knowledge of its location and also neglects multiple sites such as allosteric ones [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Water molecules often play a role in ligand binding [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>] and ignoring interfacial water positions during docking may drive the ligands into pockets which are or should be filled with water molecules, resulting in incorrectly docked ligand poses [<xref ref-type="bibr" rid="CR12">12</xref>]. Potential water release is also important during ligand binding especially through its entropic contributions [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Neglecting or limiting the flexibility of target molecules is obviously incorrect at binding situations with induced fit [<xref ref-type="bibr" rid="CR15">15</xref>]. Eventuality of random number generation in search engines such as Monte-Carlo or genetic algorithms [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] is a natural barrier of the reproducibility and reliability of the results.</p>
    <p id="Par17">The blind docking (BD) approach was introduced [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] to extend the docking search to the entire target surface. In BD, previous knowledge and restriction of the search to a primary binding site are not necessary, and therefore, it can be used in search of multiple binding sites, as well. Indeed, BD has gained popularity [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref>] and has been used for finding allosteric [<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>], or multiple [<xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR28">28</xref>] binding sites. Thus, BD addresses the above first challenge and performs a global search instead of a focused one at an increased computational cost. However, approximations ii–iv cannot be remediated as simply as the first one. Promising approaches using explicit water molecules in the binding pocket [<xref ref-type="bibr" rid="CR10">10</xref>] (approximation ii) and treating target flexibility (approximation iii) have been reported for focused docking [<xref ref-type="bibr" rid="CR29">29</xref>]. However, such approaches have not been implemented in conjunction with solving the global search problem of BD on the entire target surface. Statistical evaluation of multiple docking trials has been shown to increase reproducibility of a BD search [<xref ref-type="bibr" rid="CR17">17</xref>]; by using multiple randomized (approximation iv) initial ligand positions. Thus, it has become common to perform several docking trials with different initial positions in a BD search to ensure that the largest possible part of the target surface is scanned. However, even such a statistical evaluation cannot guarantee systematic and reproducible exploration of the entire target surface during BD.</p>
    <p id="Par18">Molecular dynamics (MD) simulations have an increasing impact on drug development [<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR32">32</xref>]. A series of pioneering studies have reported the use of MD for tracking the ligand binding process [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR37">37</xref>], at atomic resolution. MD calculations also allow the use of explicit water molecules and flexible targets overcoming the above limitations from approximations ii and iii [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>] potentially opening a new avenue for improvement of BD. MD simulations typically use random starting conformations for the ligands, likewise to BD. Generally, long MD calculation times are required for successful navigation of the ligand into the binding site such that the computational time necessary for accurate docking of a ligand may be prohibitive in practice. Pocket search methods were also developed, exploiting the above-mentioned advantages of MD [<xref ref-type="bibr" rid="CR41">41</xref>]. A recent review [<xref ref-type="bibr" rid="CR30">30</xref>] also concludes that “Improper preparation of the initial structure or insufficient equilibration of the initial structure(s) can impact the quality of the MD results”. The present study is aimed at overcoming the above uncertainties of present fast BD and molecular dynamics techniques, by combination of their advantages into a new strategy. Test applications are presented with successful identification of multiple binding sites on biologically important systems such as MAP and tyrosine-protein kinases, key players of cellular signaling as well as farnesyl pyrophosphate synthase, a target of antitumor agents.</p>
  </sec>
  <sec id="Sec2">
    <title>Algorithm</title>
    <p id="Par19">Wrap ‘n’ Shake (WnS) is a new method composed of consecutive algorithms, the Wrapper and the Shaker (Fig. <xref rid="Fig1" ref-type="fig">1</xref>, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supporting Movie 1) offering a systematic search for multiple binding sites and modes. WnS works in synergy with popular open source program packages AutoDock 4.2.3 [<xref ref-type="bibr" rid="CR29">29</xref>] and GROMACS 5.0.2 [<xref ref-type="bibr" rid="CR42">42</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Wrap ‘n’ Shake flowchart featuring the main steps of the method. A quick overview is also presented in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supporting Movie 1</p></caption><graphic xlink:href="13321_2017_255_Fig1_HTML" id="MO2"/></fig>
</p>
    <sec id="Sec3">
      <title>Wrapper</title>
      <p id="Par20">Wrapper performs several fast BD cycles by AutoDock 4.2, and AutoGrid 4.2 [<xref ref-type="bibr" rid="CR29">29</xref>] and systematically covers the entire surface of the target with a monolayer of ligand copies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Each BD cycle is performed as described in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1, and results in 100 docked ligand copies, which are ordered by their interaction energies with the target, and structurally clustered. To achieve a ligand monolayer, the ligand–ligand interactions are minimized through implementation of a weak repulsion between the docked ligand copies, and therefore blocking the formation of ligand aggregates (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2). At the same time, target-ligand interactions are maximized (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3) to ensure that the largest possible numbers of new ligand copies are placed on the surface in an actual BD cycle. The initial experiments (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2) also showed that introduction of a weak repulsion is essential to avoid erroneous ligand geometries clashing with target atoms. Such unwanted clashes (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2) were obtained if intermolecular electrostatic (E<sub>Coulomb</sub>) and van der Waals (E<sub>LJ</sub>, Eq. <xref rid="Equ1" ref-type="">1</xref>) interaction energy terms were simply switched off at the ligand atoms. Notably, calculation of total target-ligand intermolecular interaction energy (E<sub>inter</sub>) in AutoDock 4.2 is based on the scaled E<sub>Coulomb</sub> and E<sub>LJ</sub> terms of the Amber96 force field [<xref ref-type="bibr" rid="CR43">43</xref>], and an estimate for de-solvation free energy changes (ΔG<sub>sol</sub>, Eq. <xref rid="Equ1" ref-type="">1</xref>). E<sub>LJ</sub> is the sum of Lennard-Jones potential energy values (V, Fig. <xref rid="Fig2" ref-type="fig">2</xref>) calculated for all target-ligand atom pairs.<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{E}}_{\rm inter} = {\text{E}}_{\rm Coulomb} + {\text{E}}_{\rm LJ} + {\Delta\text{G}}_{\rm sol} .$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:msub><mml:mtext>E</mml:mtext><mml:mi mathvariant="normal">inter</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mtext>E</mml:mtext><mml:mi mathvariant="normal">Coulomb</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mtext>E</mml:mtext><mml:mi mathvariant="normal">LJ</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mtext>G</mml:mtext></mml:mrow><mml:mi mathvariant="normal">sol</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xlink:href="13321_2017_255_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Systematic calibration of ε<sub>X</sub> and R<sub>X</sub>. <bold>a</bold> A section of the V<sub>XO</sub>(r, ε<sub>X</sub>, R<sub>X</sub>) LJ potential function at r = 2 Å. Scenarios Sc1-Sc3 are shown with the magnitude of the R<sub>X</sub> values corresponding to a short range repulsion of V<sub>XO</sub> ≈ 1 kcal/mol (dashed lines) <bold>b</bold> V<sub>XO</sub> LJ potential functions of scenarios Sc1-Sc3. V<sub>OO</sub> of an oxygen atom pair is also shown for comparison. <bold>c</bold> An example of excluded atoms X (red, Cycle 1, Rank 2, System 9). Docked ligand conformation, is presented with sticks and the binding pocket is shown as surface. <bold>d</bold> Ligand of System 2 (dark blue sticks) bound to its target farnesyl pyrophosphate synthase (grey lines and surface) after Shaker (MD<sub>F</sub> step). Explicit water molecules surrounding the ligand within 7 Å are shown with sticks and light blue surface</p></caption><graphic xlink:href="13321_2017_255_Fig2_HTML" id="MO4"/></fig>
</p>
      <p id="Par21">Finally, instead of the above-mentioned, oversimplified attempt of switching off all intermolecular terms of E<sub>inter</sub> we elaborated a new protocol which produced the desired ligand monolayer by introduction of an excluded atom type (X). In this protocol, all ligand copies docked in a cycle and their surrounding target atoms are excluded from the next cycle (red in Fig. <xref rid="Fig2" ref-type="fig">2</xref>c), and only the unbound target surface (grey) is used for a next BD cycle. The neighboring target atoms are selected by an interface tolerance of 3.5 Å, the maximal distance between a target heavy atom and the closest docked ligand heavy atom. The above exclusion of certain atoms during docking is physically achieved by modification of the non-bonding terms of E<sub>inter</sub>. For this, the new atom type X is assigned for excluded atoms (red in Fig. <xref rid="Fig2" ref-type="fig">2</xref>c) by a C program Wrp developed for this study. Wrp switches off E<sub>Coulomb</sub> by setting the partial charge of X to zero and also assigns new LJ parameters.</p>
      <p id="Par22">The new LJ parameters were fine-tuned for atom type X in order to produce the necessary weak repulsions described above. Briefly, the LJ parameters of X were calibrated considering the pairwise LJ potential between atom types X and Y (V<sub>XY</sub>) at three common atom types (Y=O, C and H). A systematic search of both equilibrium potential well-depth (ε<sub>X</sub>, Fig. <xref rid="Fig2" ref-type="fig">2</xref>a) and inter-nuclear distance (R<sub>X</sub>) was conducted. Numerous docking runs were performed to evaluate the effect of the selected LJ parameters. A pre-defined value of r = 2 Å (ca. a covalent bond + 0.5 Å) was used as a minimal distance where short-range repulsion should act at a desired maximal value not exceeding a V<sub>XY</sub>≈1 kcal/mol. Three scenarios (Sc1-Sc3) were evaluated as shown in the r = 2 Å section of V<sub>XO</sub> (r, ε<sub>X</sub>, R<sub>X</sub>) function (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a) calculated for the XO atom type pair. Sc2 (green line, Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, b) was identified as an optimal scenario with an ε<sub>X</sub> = 10<sup>−4</sup> kcal/mol and an R<sub>X</sub> of 3.2 Å (approximate distance between heavy atoms in an H-bond). In this case, available target surface is optimally used without large ligand-free zones in the monolayer. A short-range repulsion was achieved (green line in Fig. <xref rid="Fig2" ref-type="fig">2</xref>b) with a zero value beyond the repulsion zone. If R<sub>X</sub> was too large (Sc1, red in Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, b) then the repulsion zone around the docked ligand copies would also increase with a V<sub>XO</sub> curve shifted to the right if compared to the green curve of Sc2 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b) resulting in large ligand-free zones, i.e. a non-optimal arrangement of the ligand copies in the monolayer. Importantly, the repulsion zone in the optimal V<sub>XO</sub> curve of Sc2 starts at lower distances (r) than in the V<sub>OO</sub> curve. V<sub>OO</sub> is shifted to the right of the red curve (Sc1), which would result in even larger ligand-free regions than Sc1. Thus, using only a repulsion term of V<sub>OO</sub> would have not been adequate for exclusions of atoms in wrapping. On the other hand, if R<sub>X</sub> was too small (Sc3, blue in Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, b), then unwanted attractive effects such as aggregation between docked ligand copies would still happen similar to Trial 1, in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2. Accordingly, in Sc3 the corresponding blue curve is shifted to the left from the green Sc2 curve (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). The same procedure was repeated for atom types Y = C and H and an average R<sub>X</sub> value of 3.6 Å was concluded (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3) and used in Wrapper along with the above ε<sub>X</sub> = 10<sup>−4</sup> kcal/mol.</p>
      <p id="Par23">These calibrated LJ parameters of X allowed elimination of the above-mentioned unwanted interactions between the newly docked ligand copies and the already filled binding pockets (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). As the introduced repulsive potential acts on a short range, the ligands can still dock to other, unbound parts of the target surface. The new atom type and parameters also maximize target-ligand interactions adding the maximal number of ligand copies to the mono-layer during a BD cycle.</p>
      <p id="Par24">Wrapper cycles are terminated by either the drop of uncovered surface area of the target below one percent of its total (ligand-free, initial) surface area, or positive target-ligand interaction energy in every cluster representative (EC<sub>W</sub> in Fig. <xref rid="Fig1" ref-type="fig">1</xref>). As a last step, a trimming is performed to remove all ligand copies situated more than 3.5 Å from the target. Wrapper results in a target wrapped in N ligand copies (target-ligand<sub>N</sub> complex) provided as a single Protein Databank (PDB) file. Wrapper is implemented in a new open source package WnS as shell scripts and a C program Wrp available for download together with a User’s Manual at <ext-link ext-link-type="uri" xlink:href="http://www.wnsdock.xyz">www.wnsdock.xyz</ext-link>.</p>
    </sec>
    <sec id="Sec4">
      <title>Shaker</title>
      <p id="Par25">Shaker selects functional binding sites by removing non-specific, loosely bound ligand copies from the target surface. The target-ligand<sub>N</sub> complex is placed in a box filled with water and subjected to MD simulations in consecutive cycles. The cycles are performed until a 75% of the ligand copies are eliminated (Exit Criterion of Shaker, EC<sub>S</sub> Fig. <xref rid="Fig1" ref-type="fig">1</xref>). In each Shaker cycle, distance and energy metrics are calculated describing target-ligand interactions at each time step (frame) of a trajectory. The metrics include the closest distances between the target and the ligand as well as E<sub>LJ</sub>, calculated using Amber parameters. Based on these metrics, filtering (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S4) and subsequent removal of the corresponding ligand co-ordinates (Washing, Fig. <xref rid="Fig1" ref-type="fig">1</xref>) are applied to exclude ligand positions dissociated from their starting binding positions. The filtering involves two distance-based steps and two final steps based on E<sub>LJ</sub>.</p>
      <p id="Par26">Before the first cycle a 5-ns target backbone-restrained MD (MD<sub>B</sub>) is used to grossly shake off the weakly bound ligands. In cases where this initial MD is not enough to reach the required EC<sub>S</sub> (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1 and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S7), multiple cycles with 20-ns simulated annealing (MD<sub>BSA</sub>) simulations are performed, using position restraints on the target backbone atoms. Depending on the molecular weight (MW, Table <xref rid="Tab1" ref-type="table">1</xref>) of the ligands, SA was done, using two temperature protocols, up to 50 °C (MW ≤ 300) or 80 °C (MW ≥ 300). High temperature in SA accelerated the dissociation process as expected. After MD<sub>BSA</sub> cycles, a clustering and ranking step is performed, using the last frames of the remaining ligands. A refinement of 20-ns MD with full protein flexibility (MD<sub>F</sub>) is also performed on every target-ligand complex resulted after clustering (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S7 and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S8). The Shaker protocol (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S9) was formulated during multiple trials (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Tables S5 and S6) and results in a final solution structure of a target-ligand<sub>n</sub> complex, where n is the total number of final cluster representatives.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Test systems</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">#</th><th align="left">PDB ID<sup>a</sup>
</th><th align="left">Target</th><th align="left">Ligand</th><th align="left">MW<sup>b</sup>
</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">3ptb</td><td align="left">bovine β-trypsin</td><td align="left">benzamidine</td><td char="." align="char">120</td></tr><tr><td align="left">2</td><td align="left">3n3 l</td><td align="left">farnesyl pyrophosphate synthase</td><td align="left">(6-methoxy-1-benzofuran-3-yl) acetic acid (MS0)</td><td char="." align="char">206</td></tr><tr><td align="left">3a</td><td align="left">3hvc</td><td align="left">mitogen-activated protein kinase</td><td align="left">4-[3-(4-fluorophenyl)-1 h-pyrazol-4-yl]pyridine (GG5)</td><td char="." align="char">239</td></tr><tr><td align="left">3b</td><td align="left">4f9w</td><td align="left">mitogen-activated protein kinase</td><td align="left">4-[3-(4-fluorophenyl)-1 h-pyrazol-4-yl]pyridine (GG5)</td><td char="." align="char">239</td></tr><tr><td align="left">4</td><td align="left">3cpa</td><td align="left">carboxy-peptidase</td><td align="left">GY</td><td char="." align="char">256</td></tr><tr><td align="left">5</td><td align="left">1qcf</td><td align="left">haematopoetic cell kinase (HCK)</td><td align="left">1-ter-butyl-3-p-tolyl-1 h-pyrazolo[3,4-d]pyrimidin- 4-ylamine (PP1)</td><td char="." align="char">281</td></tr><tr><td align="left">6</td><td align="left">1h61</td><td align="left">pentaerythritol tetranitrate reductase</td><td align="left">Prednisone<sup>®</sup>
</td><td char="." align="char">358</td></tr><tr><td align="left">7</td><td align="left">2bal</td><td align="left">mitogen-activated protein kinase</td><td align="left">[5-amino-1-(4- Fluorophenyl)-1H-Pyrazol-4- yl] [3-(piperidin-4-yloxy) phenyl]methanone</td><td char="." align="char">380</td></tr><tr><td align="left">8</td><td align="left">1hvy</td><td align="left">thymidylate synthase</td><td align="left">Ralitrexed<sup>®</sup>
</td><td char="." align="char">459</td></tr><tr><td align="left">9</td><td align="left">3g5d</td><td align="left">tyrosine-protein kinase Src</td><td align="left">Dasatinib<sup>®</sup>
</td><td char="." align="char">488</td></tr><tr><td align="left">10</td><td align="left">1be9</td><td align="left">PDZ-domain</td><td align="left">KQTSV</td><td char="." align="char">544</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>PDB ID of the holo X-ray structure</p><p><sup>b</sup>Molecular weight of the ligand</p></table-wrap-foot></table-wrap>
</p>
    </sec>
  </sec>
  <sec id="Sec5">
    <title>Systems and test metrics</title>
    <p id="Par27">A diverse set of ten target-ligand systems were selected (Table <xref rid="Tab1" ref-type="table">1</xref>) and prepared (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1) as test cases of WnS. Challenging systems with multiple (prerequisite or allosteric) binding sites were included (Table <xref rid="Tab1" ref-type="table">1</xref>). Our selection contains both small ligands and bulky, flexible ones. Apo protein structures were used as targets except System 8. In the case of System 5 another protein tyrosine-protein kinase was used as apo structure similar to a previous study [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
    <p id="Par28">Three standard metrics were used to quantify the results of tests. (1) root mean squared deviation (RMSD) measures structural precision of WnS results by comparison of atomic positions of ligand conformations produced by WnS and those of the crystallographic reference. Prior to calculation of RMSD, a structural alignment (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S10) was performed on the holo and apo target residues surrounding the ligand within 5 Å similarly to a previous work [<xref ref-type="bibr" rid="CR33">33</xref>]. (2) Shaker Rate (SR = N/n) is a ratio of counts of the N ligand copies residing on the target surface (N) after Wrapper and the n final cluster representatives (n) produced by Shaker. The larger the SR, the more efficiently Shaker eliminated ligand copies from the target surface. (3) Rank serial number (#Rank) is calculated using relative ligand-target interaction energies corresponding to the docked ligand positions. WnS ranks docked ligand copies by their interaction energies with the target. The smaller the #Rank, the stronger the target-ligand interaction is at a ligand position. The #Rank of the docked ligand copy of the lowest RMSD is listed for all systems in Table <xref rid="Tab2" ref-type="table">2</xref>. In the final rank lists, docked ligand copies with small RMSD, i.e. close to the crystallographic conformations should be preferably placed at the top of the rank lists, with small #Rank values.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Results for the test systems</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">#</th><th align="left" rowspan="2">N<sup>a</sup>
</th><th align="left" rowspan="2">CLS<sup>b</sup>
</th><th align="left" colspan="2">#Rank<sup>c</sup>
</th><th align="left" rowspan="2">n<sup>d</sup>
</th><th align="left" rowspan="2">SR<sup>e</sup>
</th></tr><tr><th align="left">MD<sub>BSA</sub>
</th><th align="left">MD<sub>F</sub>
</th></tr></thead><tbody><tr><td align="left">1a</td><td char="." align="char">68</td><td char="." align="char">6</td><td char="." align="char">1</td><td align="left">1</td><td char="." align="char">6</td><td char="." align="char">11</td></tr><tr><td align="left">1b<sup>g</sup>
</td><td char="." align="char">74</td><td char="." align="char">5</td><td char="." align="char">1</td><td align="left">–</td><td char="." align="char">4</td><td char="." align="char">19</td></tr><tr><td align="left">1c<sup>g</sup>
</td><td char="." align="char">71</td><td char="." align="char">6</td><td char="." align="char">1</td><td align="left">–</td><td char="." align="char">5</td><td char="." align="char">14</td></tr><tr><td align="left">2</td><td char="." align="char">300</td><td char="." align="char">18</td><td char="." align="char">2</td><td align="left">4</td><td char="." align="char">13</td><td char="." align="char">23</td></tr><tr><td align="left">3a</td><td char="." align="char">222</td><td char="." align="char">46</td><td char="." align="char">3</td><td align="left">4</td><td char="." align="char">21</td><td char="." align="char">11</td></tr><tr><td align="left">3b</td><td char="." align="char">222</td><td char="." align="char">46</td><td char="." align="char">9</td><td align="left">12</td><td char="." align="char">21</td><td char="." align="char">11</td></tr><tr><td align="left">4 <sup>h</sup>
</td><td char="." align="char">155</td><td char="." align="char">12</td><td char="." align="char">1</td><td align="left">1</td><td char="." align="char">8</td><td char="." align="char">19</td></tr><tr><td align="left">5</td><td char="." align="char">143</td><td char="." align="char">25</td><td char="." align="char">2</td><td align="left">1</td><td char="." align="char">12</td><td char="." align="char">12</td></tr><tr><td align="left">6<sup>i</sup>
</td><td char="." align="char">116</td><td char="." align="char">26</td><td char="." align="char">1</td><td align="left">2</td><td char="." align="char">12</td><td char="." align="char">10</td></tr><tr><td align="left">7</td><td char="." align="char">123</td><td char="." align="char">26</td><td char="." align="char">4</td><td align="left">4</td><td char="." align="char">12</td><td char="." align="char">10</td></tr><tr><td align="left">8</td><td char="." align="char">106</td><td char="." align="char">25</td><td char="." align="char">1</td><td align="left">1</td><td char="." align="char">10</td><td char="." align="char">11</td></tr><tr><td align="left">9<sup>j</sup>
</td><td char="." align="char">92</td><td char="." align="char">23</td><td char="." align="char">2</td><td align="left">1</td><td char="." align="char">10</td><td char="." align="char">9</td></tr><tr><td align="left">10</td><td char="." align="char">49</td><td char="." align="char">11</td><td char="." align="char">2</td><td align="left">1</td><td char="." align="char">4</td><td char="." align="char">12</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Total count of ligand copies after Wrapper</p><p><sup>b</sup>Count of ligands surviving the Shaker, after MD<sub>BSA</sub></p><p><sup>c</sup>Rank serial number of the structure with the best RMSD value, after MD<sub>BSA</sub> and after MD<sub>F</sub>
</p><p><sup>d</sup>Count of cluster representatives (final solutions) Shaker</p><p><sup>e</sup>Shaker Rate</p><p><sup>f</sup>Total computational time required for MD<sub>B</sub>, MD<sub>BSA</sub> and MD<sub>F</sub>, as explained in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S12</p><p><sup>g</sup>For System 1, WnS was performed with different seeds for data reproduction purposes</p><p><sup>h</sup>Final clustering was done using van der Waals and Coulomb interactions due to interactions of zinc ion with the ligand</p><p><sup>i</sup>Wrapper process was done, using the LJ interaction as a scoring function, instead of AD4 (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S13)</p><p><sup>j</sup>Final clustering was done with 6 Å distance limit between clusters</p></table-wrap-foot></table-wrap>
</p>
  </sec>
  <sec id="Sec6">
    <title>Results and discussion</title>
    <sec id="Sec7">
      <title>Association or dissociation?</title>
      <p id="Par29">Encouraged by results of pioneering MD studies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], association of ligand benzamidine to bovine trypsin was followed in three MD simulations. Benzamidine is an easy case for docking and it has also been used in tests of recent approaches [<xref ref-type="bibr" rid="CR44">44</xref>]. The present MD simulations were 1-µs-long and benzamidine was placed at three different starting positions (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S11), at various distances (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a) from the crystallographic binding site.<fig id="Fig3"><label>Fig. 3</label><caption><p>Pilot molecular dynamics simulations. Benzamidine ligand (sticks) started the MD simulations from three positions at different distances (as indicated in the legend) from the native binding site on the trypsin target (grey cartoon). Arrows in <bold>a</bold> point from starting (t = 0 ns) to final (t = 1000 ns) ligand positions. Only two of the three 1000 ns-long simulations with the closest starting position succeeded in finding the reference binding pose (*) known from the crystallographic structure (3ptb). <bold>b</bold> Time-dependence of root mean squared deviation (RMSD) of the ligand measured from its reference pose</p></caption><graphic xlink:href="13321_2017_255_Fig3_HTML" id="MO5"/></fig>
</p>
      <p id="Par30">Analysis of the trajectories shows that the crystallographic binding position was found in two out of the three simulations after 81 and 690 ns simulation time (drop of red and green lines in Fig. <xref rid="Fig3" ref-type="fig">3</xref>b), respectively. In the 3rd case with the largest starting distance, 1 µs was not enough to dock to the native site by association (blue line). Thus, the usefulness of association MD runs for docking strongly depends on the starting ligand position even in the easy case of benzamidine. MD needs a simulation time comparable to the real association time of the ligand (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b). This can be considerable, as migration of the ligand is hindered by friction in the surrounding water. Previous studies [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], have also reported simulations of several hundreds of nanoseconds for navigation of the ligand to the desired binding pocket.</p>
      <p id="Par31">All-in-all, the necessary time for successful docking by association MD depends on the actual starting position of the ligand, the size and shape of the target, ligand etc. To overcome such uncertainties on simulation length and still use the benefits of MD we elaborated a new strategy, the Wrap ‘n’ Shake (WnS, Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Instead of simulating the association process, WnS is based on the dissociation of the ligand. Dissociation is fast and reproducible at binding sites of low stability.</p>
    </sec>
    <sec id="Sec8">
      <title>A systematic approach</title>
      <p id="Par32">Naturally, a dissociation approach requires a set of ligand copies bound to the target. Systematic mapping of all possible ligand positions (sites) cannot be guaranteed in a single BD cycle (Introduction) even if it contains hundreds of fast BD trials [<xref ref-type="bibr" rid="CR17">17</xref>]. A truly systematic algorithm should completely wrap the entire surface of the target in a monolayer of copies of the ligand molecule. Our initial guess of such a Wrapper algorithm was based on a previous finding [<xref ref-type="bibr" rid="CR17">17</xref>] that the coverage of the target can be increased with several, successive fast BD cycles where accumulated docked ligand copies from the previous cycle are considered as part of the target in the next cycle. However, additional experiments with such successive BD cycles showed that previously and newly docked ligand copies can easily form multi-layer aggregates with each-other instead of the target (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2). The formation of such aggregates hinders wrapping of the target surface into the desired monolayer of ligand copies.</p>
      <p id="Par33">During the wrapping process, parts of the target surface already covered with ligand copies has to be excluded from interactions with ligand copies docked in a next BD cycle. This task is not trivial as potential functions of the docking force fields normally cannot distinguish between target sites unbound and covered with ligands. After extensive experimentation including an optimization of the force field (“<xref rid="Sec3" ref-type="sec">Wrapper</xref>” section, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3, Appendix 1) we arrived at a new algorithm called Wrapper (Figs. <xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig4" ref-type="fig">4</xref>). Wrapper performs a systematic coverage of the target surface in several, consecutive fast blind docking cycles (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The algorithm continuously monitors the status of coverage of target surface (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a) and results in the desired monolayer of N ligand copies not interacting with each-other. Figure <xref rid="Fig4" ref-type="fig">4</xref>b shows an example of such a monolayer. Ligands constituting the monolayer have physically realistic arrangement (Fig. <xref rid="Fig4" ref-type="fig">4</xref>c), maximized interactions with the target and no contacts with each-other. Thus, the target is systematically and rapidly wrapped in a monolayer of N (Table <xref rid="Tab2" ref-type="table">2</xref>) ligands.<fig id="Fig4"><label>Fig. 4</label><caption><p>Wrapping tyrosine-protein kinase Src target into a mono-layer of ligand copies (System 5). <bold>a</bold> Unbound (ligand free) accessible surface area (ASA) of the target and the lowest E<sub>inter</sub> of the cluster representatives in consecutive wrapping cycles. Target-ligand interaction energy (E<sub>inter</sub>) increases with increasing number of cycles finding strong binding sites in the first few cycles, before the final, saturation region. ASA finally decreases below 1%. Structural images show the wrapping of the target (grey surface) with ligands (red). <bold>b</bold> The monolayer arrangement of the ligands (red sticks) wrapping the entire target surface (grey) after the final cycles. <bold>c</bold> A close-up of a section of the monolayer showing that the ligand copies are evenly arranged without overlap</p></caption><graphic xlink:href="13321_2017_255_Fig4_HTML" id="MO6"/></fig>
</p>
      <p id="Par34">Having a realistic input geometry, the resulting target-ligand<sub>N</sub> complex is transferred to the Shaker including MD simulation(s) with explicit water (“<xref rid="Sec4" ref-type="sec">Shaker</xref>” section), filtering, and clustering steps. These steps eliminate ligands dissociated during MD and result in a strong binder at each pocket (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S7). Final results are shown in Table <xref rid="Tab2" ref-type="table">2</xref> using test metrics described in “<xref rid="Sec5" ref-type="sec">Systems and test metrics</xref>”. Parameter SR characterizes efficiency of removal of loose binders. SR values of Table <xref rid="Tab2" ref-type="table">2</xref> indicate that a considerably large part of the weak binders were efficiently removed at all test systems beyond the default EC<sub>S</sub> of 75% (SR = 4). Other important metrics are RMSD and #Rank. In most of the systems analyzed, ligand conformations with the lowest RMSD were placed into the first two ranks (Table <xref rid="Tab2" ref-type="table">2</xref>, Fig. <xref rid="Fig5" ref-type="fig">5</xref>, and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S8). For stable ligand copies, good structural matches to the corresponding reference conformations (Fig. <xref rid="Fig5" ref-type="fig">5</xref> and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S8), as well as low #Rank values (Table <xref rid="Tab2" ref-type="table">2</xref>) were found. Fair results were obtained for challenging cases too (Systems 2 and 3). The somewhat lower rank in these cases may be explained by the relatively high B-factor of the ligands of these systems (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1) suggesting an increased mobility and a less stable target-ligand interaction.<fig id="Fig5"><label>Fig. 5</label><caption><p>Structural fits quantified as root mean squared deviation (RMSD) with values given in Å. Ligand conformations after Shaker (grey) compared to the crystallographic references (red sticks). System# is bold</p></caption><graphic xlink:href="13321_2017_255_Fig5_HTML" id="MO7"/></fig>
</p>
      <p id="Par35">For example, B-factors of measured atomic positions of ligand MSo (System 2) vary in a range between 54 and 95 Å<sup>2</sup> (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1). During MD<sub>F</sub> simulations we found that the RMSD varied between 2.5 and 5.1 Å (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S8), and a final #Rank of 4 and an RMSD of 3.1 Å were obtained. Considering the above high B-factor values, it is realistic to assume that ligand MSo adopts various conformations when bound to farnesyl phosphate synthase (System 2) including the one close to the assigned position found with an RMSD of 2.5 Å. This conformational variability of the bound MSo is probably due to its carboxylate group with the highest B-factor of 95 Å<sup>2</sup>. This group is hydrated by bulk water molecules, helping the dissociation of MSo from the target (Fig. <xref rid="Fig2" ref-type="fig">2</xref>d). At the same time, MD simulations with explicit water molecules also account for a hydrophobic, anchoring interaction between the benzofuran part of MSo (no waters present, Fig. <xref rid="Fig2" ref-type="fig">2</xref>d) and the target. This example shows the necessity of use of explicit water model during the shaking process in order to account for all, even antagonistic interactions.</p>
      <p id="Par36">In our pilot study (“<xref rid="Sec7" ref-type="sec">Association or dissociation?</xref>” section) it was demonstrated that MD methods following the association pathways often need large amount of computational time and/or a fortunate starting conformation in order to find the primary site correctly for System 1. WnS yielded the correct solution for this system (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S8) in a 5-ns-long MD<sub>B</sub> simulation which is at least one order of magnitude shorter than the lengthy association times discussed in “<xref rid="Sec7" ref-type="sec">Association or dissociation?</xref>” section. Elimination of ligand excess (dissociation of ligand copies) (Tables S14 and S15) at an SR of 11 was facilitated by hydrogen bonding with explicit water molecules [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Thermal motion of water molecules also contributed to fast “shake off” of the ligand copies especially in the cases of Systems with small ligands with the application of the simulated annealing protocol (MD<sub>BSA</sub>, see an SR of 23 in case of System 2 in Table <xref rid="Tab2" ref-type="table">2</xref>).</p>
    </sec>
    <sec id="Sec9">
      <title>A case with a small ligand</title>
      <p id="Par37">WnS was tested on tyrosine protein kinase target with a pyrazolopyrimidine 1 ligand (PP1, System 5). Regulation of kinase activity is important in numerous human diseases [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. At the same time, this kinase is a challenging test target for WnS as it has multiple sites including an allosteric one identified in previous studies [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. The native, PP1 site was found (Fig. <xref rid="Fig5" ref-type="fig">5</xref>) at an excellent RMSD agreement (1.4 Å, Fig. <xref rid="Fig5" ref-type="fig">5</xref>) with the crystallographic position. Besides obtaining very good RMSD (Fig. <xref rid="Fig5" ref-type="fig">5</xref>), the #Rank was improved from second to first place (Table <xref rid="Tab2" ref-type="table">2</xref>) during the final MD<sub>F</sub> simulation (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S16). Apart from the primary site, our goal was to find other, prerequisite binding sites, as well. As described in a previous MD study [<xref ref-type="bibr" rid="CR33">33</xref>], such sites correspond to poses on the binding pathway leading to the primary site. WnS found both low- and high energy prerequisite sites described previously [<xref ref-type="bibr" rid="CR33">33</xref>] (Fig. <xref rid="Fig6" ref-type="fig">6</xref>). Besides structural matches, #Rank and the corresponding energy values are also comparable to the previous results. Notably, WnS can predict multiple binding sites beyond experimentally observable ones. These binding sites can be considered as prerequisite or allosteric binding sites. Previous MD results [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] concluded, that finding prerequisite binding sites is a substantial advantage of the MD simulations.<fig id="Fig6"><label>Fig. 6</label><caption><p>Haematopoetic cell kinase (HCK, System 5) with ligand copies remaining after Shaker. Ligand copies are colored by the calculated target-ligand interaction energy E, and the #Rank assigned. The previously reported pockets 1(ATP), 2(A-loop), 3(PIF site), 4(G-loop) and 5(MYR) are numbered by their increasing E<sub>LJ</sub>
</p></caption><graphic xlink:href="13321_2017_255_Fig6_HTML" id="MO8"/></fig>
</p>
    </sec>
    <sec id="Sec10">
      <title>Cases with large ligands</title>
      <p id="Par38">Tyrosine kinase also binds dasatinib (System 9), a bulky ligand, for which an SR of 9 was obtained (Table <xref rid="Tab2" ref-type="table">2</xref>), after six simulated annealing cycles (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S12). The same four binding pockets were found for dasatinib as for the above PP1 (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S17). After the final MD<sub>F</sub> step, local conformational refinement of dasatinib was observed, improving the RMSD from 2.3 to 1.9 Å. Similar to PP1, this could be partially explained by the role of the water molecules and the enhanced target motion during MD<sub>BSA</sub>. WnS was further tested on the challenging System 10 with a pentapeptide ligand with twenty-three flexible torsions. The correct binding position of the ligand was obtained after the MD<sub>F</sub> stage of Shaker with an improvement of RMSD from 6.8 to 1.7 Å (Fig. <xref rid="Fig7" ref-type="fig">7</xref>, Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Supporting Movie 2).<fig id="Fig7"><label>Fig. 7</label><caption><p>During Shaker, conformational changes of the pentapeptide KQTSV are observed, while remains bound to its pocket on the PDZ domain (System 10). Red sticks represent the native ligand conformation from PDB (1be9). Teal sticks represent ligand conformations at different Shaker stages starting with the conformation right after Wrapper (<bold>1</bold>), and continuing with conformation after MD<sub>BSA</sub> (<bold>2</bold>), and after MD<sub>F</sub> (<bold>3</bold>). The changes of target-ligand interaction energy (E<sub>LJ</sub>) and the RMSD during the MD stages in the Shaker protocol are plotted below the structural snapshots. See also Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Supporting Movie 2 for further details of conformational changes</p></caption><graphic xlink:href="13321_2017_255_Fig7_HTML" id="MO9"/></fig>
</p>
      <p id="Par39">A re-ranking (Table <xref rid="Tab2" ref-type="table">2</xref>) from Rank 2 to Rank 1 was also observed after MD<sub>F</sub>. For comparison, the wrapped target-ligand<sub>N</sub> complex of System 10 was subjected directly to an MD<sub>F</sub> simulation skipping the MD<sub>B</sub> and MD<sub>BSA</sub> steps of Shaker. In this case, an RMSD of 11.3 Å (Line 10b in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S8) was obtained which was worse than the RMSD obtained with the complete Shaker protocol (1.7 Å, Fig. <xref rid="Fig5" ref-type="fig">5</xref>). This demonstrates that both MD<sub>B</sub> and MD<sub>BSA</sub> steps of Shaker are necessary to find the correct position. After Wrapper, the pentapeptide was in a closed, cyclic conformation (Fig. <xref rid="Fig7" ref-type="fig">7</xref>, Snapshot 1). This unrealistic arrangement was opened up (Snapshots 2 and 3) by interacting water molecules. It can be also observed that limited protein flexibility during MD<sub>B</sub> and MD<sub>BSA</sub> allowed only moderate reduction of the ligand RMSD by improvement of the target-ligand interactions. Most of the RMSD and interaction energy improvement was achieved after MD<sub>F</sub>, and rearrangement of K380 inside the pocket was necessary, to improve the conformation of the simulated ligand (Fig. <xref rid="Fig7" ref-type="fig">7</xref>). All-in-all, MD steps including target flexibility have a significant influence on the results of WnS for large ligands. Introduction of MD<sub>F</sub> considerably improved structural precision, in the above case studies of large ligands (Systems 9 and 10).</p>
    </sec>
  </sec>
  <sec id="Sec11" sec-type="conclusion">
    <title>Conclusions</title>
    <p id="Par40">In the present study, a systematic strategy, the Wrap ‘n’ Shake was introduced for exploration of multiple binding sites and modes of drugs on their macromolecular targets. Wrap ‘n’ Shake systematically wraps the target into a monolayer of ligand copies using a modified blind docking approach and selects stable positions by shaking off loose binders. The method offers a computationally feasible solution for the present problems of the field (Introduction). Wrapper requires only fast blind docking cycles with a program package such as AutoDock 4.2.3. The Shaker process is fairly short and can be performed by available MD packages. Shaker is further accelerated by simulated annealing and uses all benefits of explicit water model and target flexibility. Wrap ‘n’ Shake is suitable to study interactions of protein targets with even large peptide ligands. We have started the extension of the method towards protein ligands using a fragment-based approach with post hoc reconstruction of the ligand. In future applications, Wrap ‘n’ Shake could be also used for general pocket search, besides docking of individual ligands. We envision that Wrap ‘n’ Shake can become the tool of choice for systematic exploration of multiple binding sites and modes of ligands in drug design and structural biology.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Additional files</title>
    <sec id="Sec12">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13321_2017_255_MOESM1_ESM.mpg">
            <caption>
              <p><bold>Additional file 1.</bold> Supporting Movie 1 featuring the processes of Wrapper and Shaker in the case of System 5. The first part presents the results of 15 wrapping cycles. The second part contains MD<sub>B</sub> and two MD<sub>BSA</sub> cycles of Shaker. Final cluster representatives are the outputs of WnS. Additional refinement steps are shown in Supporting Movie 2 (Additional file <xref rid="MOESM3" ref-type="media">3</xref>).</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="13321_2017_255_MOESM2_ESM.pdf">
            <caption>
              <p><bold>Additional file 2.</bold> Supporting Tables S1–S17 and Appendix 1–4 with detailed methods and results.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="13321_2017_255_MOESM3_ESM.mpg">
            <caption>
              <p><bold>Additional file 3.</bold> Supporting Movie 2 featuring conformational changes of pentapeptide KQTSV, bound to PDZ-domain (System 10) during 65 ns simulations performed Shaker. The binding pocket of KQTSV on the PDZ domain is presented with grey surface. The simulated and crystallographic reference structures of KQTSV are presented as teal and red sticks.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>BD</term>
        <def>
          <p id="Par4">blind docking</p>
        </def>
      </def-item>
      <def-item>
        <term>EC<sub>W</sub></term>
        <def>
          <p id="Par5">exit criterion of Wrapper</p>
        </def>
      </def-item>
      <def-item>
        <term>EC<sub>S</sub></term>
        <def>
          <p id="Par6">exit criterion of Shaker</p>
        </def>
      </def-item>
      <def-item>
        <term>E<sub>inter</sub></term>
        <def>
          <p id="Par7">intermolecular interaction energy</p>
        </def>
      </def-item>
      <def-item>
        <term>E<sub>LJ</sub></term>
        <def>
          <p id="Par8">Lennard-Jones potential</p>
        </def>
      </def-item>
      <def-item>
        <term>MD<sub>B</sub></term>
        <def>
          <p id="Par9">molecular dynamics with backbone position restraints</p>
        </def>
      </def-item>
      <def-item>
        <term>MD<sub>BSA</sub></term>
        <def>
          <p id="Par10">molecular dynamics with backbone position restraints and simulated annealing</p>
        </def>
      </def-item>
      <def-item>
        <term>MD<sub>F</sub></term>
        <def>
          <p id="Par11">molecular dynamics without restraints (flexible simulation</p>
        </def>
      </def-item>
      <def-item>
        <term>PDB</term>
        <def>
          <p id="Par12">protein data bank</p>
        </def>
      </def-item>
      <def-item>
        <term>RMSD</term>
        <def>
          <p id="Par13">root mean squared deviation</p>
        </def>
      </def-item>
      <def-item>
        <term>SR</term>
        <def>
          <p id="Par14">Shaker Rate</p>
        </def>
      </def-item>
      <def-item>
        <term>WnS</term>
        <def>
          <p id="Par15">Wrap ‘n’ Shake</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Electronic supplementary material</bold>
      </p>
      <p>The online version of this article (10.1186/s13321-017-0255-6) contains supplementary material, which is available to authorized users.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Authors’ contributions</title>
    <p>MB, CH, NJ, and IH performed research. MB, CH, and DvdS designed research, and wrote the manuscript. All authors formulated the research. All authors read and approved the final manuscript.</p>
    <sec id="FPar1">
      <title>Acknowledgements</title>
      <p id="Par41">We acknowledge a grant of computer time from CSCS Swiss National Supercomputing Centre, and NIIF Hungarian National Information Infrastructure Development Institute. We acknowledge that the results of this research have been achieved using the DECI resource Archer based in the UK at the National Supercomputing Service with support from the PRACE aisbl.</p>
    </sec>
    <sec id="FPar2">
      <title>Competing interests</title>
      <p id="Par42">The authors declare that they have no competing interests.</p>
    </sec>
    <sec id="FPar3">
      <title>Availability of data and materials</title>
      <p id="Par43">A software package is released under the GNU GPL, freely accessible with examples and a manual at <ext-link ext-link-type="uri" xlink:href="http://www.wnsdock.xyz">http://www.wnsdock.xyz</ext-link>.</p>
    </sec>
    <sec id="FPar4">
      <title>Consent for publication</title>
      <p id="Par44">Not applicable.</p>
    </sec>
    <sec id="FPar5">
      <title>Ethics approval and consent to participate</title>
      <p id="Par45">Not applicable.</p>
    </sec>
    <sec id="FPar6">
      <title>Funding</title>
      <p id="Par46">The work was supported by the K123836, K112807, K120391 grants from the National Research, Development, and Innovation Office, Hungary. The University of Pécs is acknowledged for a grant PTE ÁOK_KA/2017 and also support in the frame of “Viral Pathogenesis” Talent Centre program. We are thankful to the Gedeon Richter Pharmaceutical Plc. for a pre-doctoral scholarship to N.J.</p>
    </sec>
    <sec id="FPar7">
      <title>Publisher’s Note</title>
      <p id="Par47">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </sec>
  </ack>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kitchen</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Decornez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Furr</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Bajorath</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Docking and scoring in virtual screening for drug discovery: methods and applications</article-title>
        <source>Nat Rev Drug Discov</source>
        <year>2004</year>
        <volume>3</volume>
        <fpage>935</fpage>
        <lpage>949</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd1549</pub-id>
        <pub-id pub-id-type="pmid">15520816</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fischer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Coleman</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Fraser</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Shoichet</surname>
            <given-names>BK</given-names>
          </name>
        </person-group>
        <article-title>Incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery</article-title>
        <source>Nat Chem</source>
        <year>2014</year>
        <volume>6</volume>
        <fpage>575</fpage>
        <lpage>583</lpage>
        <pub-id pub-id-type="doi">10.1038/nchem.1954</pub-id>
        <pub-id pub-id-type="pmid">24950326</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hou</surname>
            <given-names>XB</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>KS</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Protein flexibility in docking-based virtual screening: discovery of novel lymphoid-specific tyrosine phosphatase inhibitors using multiple crystal structures</article-title>
        <source>J Chem Inf Modeling</source>
        <year>2015</year>
        <volume>55</volume>
        <fpage>1973</fpage>
        <lpage>1983</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00344</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pan</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Borhani</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Dror</surname>
            <given-names>RO</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>DE</given-names>
          </name>
        </person-group>
        <article-title>Molecular determinants of drug–receptor binding kinetics</article-title>
        <source>Drug Discov Today</source>
        <year>2013</year>
        <volume>18</volume>
        <fpage>667</fpage>
        <lpage>673</lpage>
        <pub-id pub-id-type="doi">10.1016/j.drudis.2013.02.007</pub-id>
        <pub-id pub-id-type="pmid">23454741</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Halperin</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>BY</given-names>
          </name>
          <name>
            <surname>Wolfson</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nussinov</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Principles of docking: an overview of search algorithms and a guide to scoring functions</article-title>
        <source>Proteins Struct Funct Genet</source>
        <year>2007</year>
        <volume>47</volume>
        <fpage>409</fpage>
        <lpage>443</lpage>
        <pub-id pub-id-type="doi">10.1002/prot.10115</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brooijmans</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kuntz</surname>
            <given-names>ID</given-names>
          </name>
        </person-group>
        <article-title>Molecular recognition and docking algorithms</article-title>
        <source>Annu Rev Biophys Biomol Struct</source>
        <year>2003</year>
        <volume>32</volume>
        <fpage>335</fpage>
        <lpage>373</lpage>
        <pub-id pub-id-type="doi">10.1146/annurev.biophys.32.110601.142532</pub-id>
        <pub-id pub-id-type="pmid">12574069</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iorga</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Herlem</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Barre</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Guillou</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the “blind docking” approach</article-title>
        <source>J Mol Modeling</source>
        <year>2006</year>
        <volume>12</volume>
        <fpage>366</fpage>
        <lpage>372</lpage>
        <pub-id pub-id-type="doi">10.1007/s00894-005-0057-z</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Othman</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kiat</surname>
            <given-names>TS</given-names>
          </name>
          <name>
            <surname>Khalid</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Yusof</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Newhouse</surname>
            <given-names>EI</given-names>
          </name>
          <name>
            <surname>Newhouse</surname>
            <given-names>JS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Docking of noncompetitive inhibitors into dengue virus type 2 protease: understanding the interactions with allosteric binding sites</article-title>
        <source>J Chem Inf Modeling</source>
        <year>2008</year>
        <volume>48</volume>
        <fpage>1582</fpage>
        <lpage>1591</lpage>
        <pub-id pub-id-type="doi">10.1021/ci700388k</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mancera</surname>
            <given-names>RL</given-names>
          </name>
        </person-group>
        <article-title>Molecular modeling of hydration in drug design</article-title>
        <source>Curr Opin Drug Discov Dev</source>
        <year>2007</year>
        <volume>10</volume>
        <fpage>275</fpage>
        <lpage>280</lpage>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jeszenoi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Bálint</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Horváth</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Van Der Spoel</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hetényi</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Exploration of interfacial hydration networks of target–ligand complexes</article-title>
        <source>J Chem Inf Modeling</source>
        <year>2016</year>
        <volume>56</volume>
        <fpage>148</fpage>
        <lpage>158</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00638</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jeszenoi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Horvath</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Balint</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>van der Spoel</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hetenyi</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Mobility-based prediction of hydration structures of protein surfaces</article-title>
        <source>Bioinformatics</source>
        <year>2015</year>
        <volume>31</volume>
        <fpage>1959</fpage>
        <lpage>1965</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btv093</pub-id>
        <pub-id pub-id-type="pmid">25682067</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hetenyi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>van der Spoel</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Toward prediction of functional protein pockets using blind docking and pocket search algorithms</article-title>
        <source>Protein Sci</source>
        <year>2011</year>
        <volume>20</volume>
        <fpage>880</fpage>
        <lpage>893</lpage>
        <pub-id pub-id-type="doi">10.1002/pro.618</pub-id>
        <pub-id pub-id-type="pmid">21413095</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ahmad</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Helms</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Lengauer</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kalinina</surname>
            <given-names>OV</given-names>
          </name>
        </person-group>
        <article-title>Enthalpy–entropy compensation upon molecular conformational changes</article-title>
        <source>J Chem Theory Comput</source>
        <year>2015</year>
        <volume>11</volume>
        <fpage>1410</fpage>
        <lpage>1418</lpage>
        <pub-id pub-id-type="doi">10.1021/ct501161t</pub-id>
        <pub-id pub-id-type="pmid">26574352</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ahmad</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kalinina</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Lengauer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Entropy gain due to water release upon ligand binding</article-title>
        <source>J Cheminform</source>
        <year>2014</year>
        <volume>6</volume>
        <issue>1</issue>
        <fpage>P35</fpage>
        <pub-id pub-id-type="doi">10.1186/1758-2946-6-S1-P35</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rastelli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Pacchioni</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sirawaraporn</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sirawaraporn</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Parenti</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Ferrari</surname>
            <given-names>AM</given-names>
          </name>
        </person-group>
        <article-title>Docking and database screening reveal new classes of plasmodium falciparum dihydrofolate reductase inhibitors</article-title>
        <source>J Med Chem</source>
        <year>2003</year>
        <volume>46</volume>
        <fpage>2834</fpage>
        <lpage>2845</lpage>
        <pub-id pub-id-type="doi">10.1021/jm030781p</pub-id>
        <pub-id pub-id-type="pmid">12825927</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hetenyi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>van der Spoel</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Efficient docking of peptides to proteins without prior knowledge of the binding site</article-title>
        <source>Protein Sci</source>
        <year>2002</year>
        <volume>11</volume>
        <fpage>1729</fpage>
        <lpage>1737</lpage>
        <pub-id pub-id-type="doi">10.1110/ps.0202302</pub-id>
        <pub-id pub-id-type="pmid">12070326</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hetenyi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>van der Spoel</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Blind docking of drug-sized compounds to proteins with up to a thousand residues</article-title>
        <source>FEBS Lett</source>
        <year>2006</year>
        <volume>580</volume>
        <fpage>1447</fpage>
        <lpage>1450</lpage>
        <pub-id pub-id-type="doi">10.1016/j.febslet.2006.01.074</pub-id>
        <pub-id pub-id-type="pmid">16460734</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Grinter</surname>
            <given-names>SZ</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design</article-title>
        <source>Molecules</source>
        <year>2014</year>
        <volume>19</volume>
        <fpage>10150</fpage>
        <lpage>10176</lpage>
        <pub-id pub-id-type="doi">10.3390/molecules190710150</pub-id>
        <pub-id pub-id-type="pmid">25019558</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yuriev</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Holien</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ramsland</surname>
            <given-names>PA</given-names>
          </name>
        </person-group>
        <article-title>Improvements, trends, and new ideas in molecular docking: 2012–2013 in review</article-title>
        <source>J Mol Recognit</source>
        <year>2015</year>
        <volume>28</volume>
        <fpage>581</fpage>
        <lpage>604</lpage>
        <pub-id pub-id-type="doi">10.1002/jmr.2471</pub-id>
        <pub-id pub-id-type="pmid">25808539</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yuriev</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ramsland</surname>
            <given-names>PA</given-names>
          </name>
        </person-group>
        <article-title>Latest developments in molecular docking: 2010–2011 in review</article-title>
        <source>J Mol Recognit</source>
        <year>2013</year>
        <volume>26</volume>
        <fpage>215</fpage>
        <lpage>239</lpage>
        <pub-id pub-id-type="doi">10.1002/jmr.2266</pub-id>
        <pub-id pub-id-type="pmid">23526775</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hocker</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Rambahal</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Gorfe</surname>
            <given-names>AA</given-names>
          </name>
        </person-group>
        <article-title>LIBSA—a method for the determination of ligand-binding preference to allosteric sites on receptor ensembles</article-title>
        <source>J Chem Inf Model</source>
        <year>2014</year>
        <volume>54</volume>
        <fpage>530</fpage>
        <lpage>538</lpage>
        <pub-id pub-id-type="doi">10.1021/ci400474u</pub-id>
        <pub-id pub-id-type="pmid">24437606</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schindler</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>de Vries</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Zacharias</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Fully blind peptide-protein docking with pepATTRACT</article-title>
        <source>Structure</source>
        <year>2015</year>
        <volume>23</volume>
        <fpage>1507</fpage>
        <lpage>1515</lpage>
        <pub-id pub-id-type="doi">10.1016/j.str.2015.05.021</pub-id>
        <pub-id pub-id-type="pmid">26146186</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Whalen</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>Tussey</surname>
            <given-names>KB</given-names>
          </name>
          <name>
            <surname>Blanke</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Spies</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Nature of allosteric inhibition in glutamate racemase: discovery and characterization of a cryptic inhibitory pocket using atomistic MD simulations and pK(a) calculations</article-title>
        <source>J Phys Chem B.</source>
        <year>2011</year>
        <volume>115</volume>
        <fpage>3416</fpage>
        <lpage>3424</lpage>
        <pub-id pub-id-type="doi">10.1021/jp201037t</pub-id>
        <pub-id pub-id-type="pmid">21395329</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garcia-Sosa</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Sild</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Maran</surname>
            <given-names>U</given-names>
          </name>
        </person-group>
        <article-title>Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant</article-title>
        <source>J Chem Inf Modeling</source>
        <year>2008</year>
        <volume>48</volume>
        <fpage>2074</fpage>
        <lpage>2080</lpage>
        <pub-id pub-id-type="doi">10.1021/ci800242z</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Roumenina</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bureeva</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kantardjiev</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Karlinsky</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Andia-Pravdivy</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Sim</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Complement C1q-target proteins recognition is inhibited by electric moment effectors</article-title>
        <source>J Mol Recognit</source>
        <year>2007</year>
        <volume>20</volume>
        <fpage>405</fpage>
        <lpage>415</lpage>
        <pub-id pub-id-type="doi">10.1002/jmr.853</pub-id>
        <pub-id pub-id-type="pmid">17929239</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bugatti</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Giagulli</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Urbinati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Caccuri</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Chiodelli</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Oreste</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists</article-title>
        <source>J Biol Chem</source>
        <year>2013</year>
        <volume>288</volume>
        <fpage>1150</fpage>
        <lpage>1161</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M112.400077</pub-id>
        <pub-id pub-id-type="pmid">23166320</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kovacs</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Toth</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hetenyi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Malnasi-Csizmadia</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sellers</surname>
            <given-names>JR</given-names>
          </name>
        </person-group>
        <article-title>Mechanism of blebbistatin inhibition of myosin II</article-title>
        <source>J Biol Chem</source>
        <year>2004</year>
        <volume>279</volume>
        <fpage>35557</fpage>
        <lpage>35563</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M405319200</pub-id>
        <pub-id pub-id-type="pmid">15205456</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Agarwal</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Annamalai</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Khursheed</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Maiti</surname>
            <given-names>TK</given-names>
          </name>
          <name>
            <surname>Bin Arsad</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Siddiqui</surname>
            <given-names>MH</given-names>
          </name>
        </person-group>
        <article-title>Molecular docking and dynamic simulation evaluation of Rohinitib—Cantharidin based novel HSF1 inhibitors for cancer therapy</article-title>
        <source>J Mol Graph Modelling</source>
        <year>2015</year>
        <volume>61</volume>
        <fpage>141</fpage>
        <lpage>149</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jmgm.2015.07.003</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Huey</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lindstrom</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sanner</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Belew</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Goodsell</surname>
            <given-names>DS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title>
        <source>J Comput Chem</source>
        <year>2009</year>
        <volume>30</volume>
        <fpage>2785</fpage>
        <lpage>2791</lpage>
        <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>
        <pub-id pub-id-type="pmid">19399780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ganesan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Coote</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Barakat</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Molecular dynamics-driven drug discovery: leaping forward with confidence</article-title>
        <source>Drug Discov Today</source>
        <year>2017</year>
        <volume>22</volume>
        <fpage>249</fpage>
        <lpage>269</lpage>
        <pub-id pub-id-type="doi">10.1016/j.drudis.2016.11.001</pub-id>
        <pub-id pub-id-type="pmid">27890821</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dror</surname>
            <given-names>RO</given-names>
          </name>
          <name>
            <surname>Dirks</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Grossman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>DE</given-names>
          </name>
        </person-group>
        <article-title>Biomolecular simulation: a computational microscope for molecular biology</article-title>
        <source>Annu Rev Biophys</source>
        <year>2012</year>
        <volume>41</volume>
        <fpage>429</fpage>
        <lpage>452</lpage>
        <pub-id pub-id-type="doi">10.1146/annurev-biophys-042910-155245</pub-id>
        <pub-id pub-id-type="pmid">22577825</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Durrant</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>McCammon</surname>
            <given-names>JA</given-names>
          </name>
        </person-group>
        <article-title>Molecular dynamics simulations and drug discovery</article-title>
        <source>BMC Biol</source>
        <year>2011</year>
        <volume>9</volume>
        <fpage>71</fpage>
        <pub-id pub-id-type="doi">10.1186/1741-7007-9-71</pub-id>
        <pub-id pub-id-type="pmid">22035460</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shan</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>ET</given-names>
          </name>
          <name>
            <surname>Eastwood</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Dror</surname>
            <given-names>RO</given-names>
          </name>
          <name>
            <surname>Seeliger</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>DE</given-names>
          </name>
        </person-group>
        <article-title>How does a drug molecule find its target binding site?</article-title>
        <source>J Am Chem Soc</source>
        <year>2011</year>
        <volume>133</volume>
        <fpage>9181</fpage>
        <lpage>9183</lpage>
        <pub-id pub-id-type="doi">10.1021/ja202726y</pub-id>
        <pub-id pub-id-type="pmid">21545110</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Buch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Giorgino</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>De Fabritiis</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations</article-title>
        <source>Proc Natl Acad Sci USA</source>
        <year>2011</year>
        <volume>108</volume>
        <fpage>10184</fpage>
        <lpage>10189</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1103547108</pub-id>
        <pub-id pub-id-type="pmid">21646537</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Limongelli</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Bonomi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Parrinello</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Funnel metadynamics as accurate binding free-energy method</article-title>
        <source>Proc Natl Acad Sci USA</source>
        <year>2013</year>
        <volume>110</volume>
        <fpage>6358</fpage>
        <lpage>6363</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1303186110</pub-id>
        <pub-id pub-id-type="pmid">23553839</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shan</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gnanasambandan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ungureanu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>ET</given-names>
          </name>
          <name>
            <surname>Hammaren</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yamashita</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase</article-title>
        <source>Nat Struct Mol Biol</source>
        <year>2014</year>
        <volume>21</volume>
        <fpage>579</fpage>
        <lpage>584</lpage>
        <pub-id pub-id-type="doi">10.1038/nsmb.2849</pub-id>
        <pub-id pub-id-type="pmid">24918548</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jensen</surname>
            <given-names>MØ</given-names>
          </name>
          <name>
            <surname>Jogini</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Borhani</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Leffler</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Dror</surname>
            <given-names>RO</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>DE</given-names>
          </name>
        </person-group>
        <article-title>Mechanism of voltage gating in potassium channels</article-title>
        <source>Science</source>
        <year>2012</year>
        <volume>336</volume>
        <issue>6078</issue>
        <fpage>229</fpage>
        <lpage>233</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1216533</pub-id>
        <pub-id pub-id-type="pmid">22499946</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Borhani</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>DE</given-names>
          </name>
        </person-group>
        <article-title>The future of molecular dynamics simulations in drug discovery</article-title>
        <source>J Comput Aided Mol Des</source>
        <year>2012</year>
        <volume>26</volume>
        <fpage>15</fpage>
        <lpage>26</lpage>
        <pub-id pub-id-type="doi">10.1007/s10822-011-9517-y</pub-id>
        <pub-id pub-id-type="pmid">22183577</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Casasnovas</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Limongelli</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Tiwary</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Carloni</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Parrinello</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Unbinding kinetics of a p38 MAP kinase type II inhibitor from metadynamics simulations</article-title>
        <source>J Am Chem Soc</source>
        <year>2017</year>
        <volume>139</volume>
        <fpage>1480</fpage>
        <lpage>4788</lpage>
        <pub-id pub-id-type="doi">10.1021/jacs.6b12950</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kuzmanic</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sutto</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Saladino</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Nebreda</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Gervasio</surname>
            <given-names>FL</given-names>
          </name>
          <name>
            <surname>Orozco</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Changes in the free-energy landscape of p38α MAP kinase through its canonical activation and binding events as studied by enhanced molecular dynamics simulations</article-title>
        <source>eLife</source>
        <year>2017</year>
        <volume>6</volume>
        <fpage>e22175</fpage>
        <pub-id pub-id-type="doi">10.7554/eLife.22175</pub-id>
        <pub-id pub-id-type="pmid">28445123</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Prakash</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hancock</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Gorfe</surname>
            <given-names>AA</given-names>
          </name>
        </person-group>
        <article-title>Binding hotspots on K-ras: consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis</article-title>
        <source>Proteins Struct Funct Bioinform</source>
        <year>2015</year>
        <volume>83</volume>
        <fpage>898</fpage>
        <lpage>909</lpage>
        <pub-id pub-id-type="doi">10.1002/prot.24786</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Abraham</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Murtola</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Schulz</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Páll</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Hess</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title>
        <source>SoftwareX</source>
        <year>2015</year>
        <volume>1</volume>
        <fpage>19</fpage>
        <lpage>25</lpage>
        <pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cornell</surname>
            <given-names>WD</given-names>
          </name>
          <name>
            <surname>Cieplak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bayly</surname>
            <given-names>CI</given-names>
          </name>
          <name>
            <surname>Gould</surname>
            <given-names>IR</given-names>
          </name>
          <name>
            <surname>Merz</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Ferguson</surname>
            <given-names>DM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules</article-title>
        <source>J Am Chem Soc</source>
        <year>1995</year>
        <volume>117</volume>
        <fpage>5179</fpage>
        <lpage>5197</lpage>
        <pub-id pub-id-type="doi">10.1021/ja00124a002</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Soderhjelm</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Tribello</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Parrinello</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Locating binding poses in protein-ligand systems using reconnaissance metadynamics</article-title>
        <source>Proc Natl Acad Sci USA</source>
        <year>2012</year>
        <volume>109</volume>
        <fpage>5170</fpage>
        <lpage>5175</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1201940109</pub-id>
        <pub-id pub-id-type="pmid">22440749</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dror</surname>
            <given-names>RO</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Arlow</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Borhani</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Maragakis</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Shan</surname>
            <given-names>YB</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pathway and mechanism of drug binding to G-protein-coupled receptors</article-title>
        <source>Biophys J</source>
        <year>2012</year>
        <volume>102</volume>
        <fpage>410</fpage>
        <pub-id pub-id-type="doi">10.1016/j.bpj.2011.11.2241</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van der Spoel</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>van Maaren</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Timneanu</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Thermodynamics of hydrogen bonding in hydrophilic and hydrophobic media</article-title>
        <source>J Phys Chem B</source>
        <year>2006</year>
        <volume>09</volume>
        <issue>110</issue>
        <fpage>4393</fpage>
        <lpage>4398</lpage>
        <pub-id pub-id-type="doi">10.1021/jp0572535</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schmidtke</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Luque</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Barril</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design</article-title>
        <source>J Am Chem Soc</source>
        <year>2011</year>
        <volume>133</volume>
        <fpage>18903</fpage>
        <lpage>18910</lpage>
        <pub-id pub-id-type="doi">10.1021/ja207494u</pub-id>
        <pub-id pub-id-type="pmid">21981450</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cohen</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Protein kinases—the major drug targets of the twenty-first century?</article-title>
        <source>Nat Rev Drug Discov</source>
        <year>2002</year>
        <volume>1</volume>
        <fpage>309</fpage>
        <lpage>315</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd773</pub-id>
        <pub-id pub-id-type="pmid">12120282</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shukla</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Roux</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pande</surname>
            <given-names>VS</given-names>
          </name>
        </person-group>
        <article-title>Activation pathway of Src kinase reveals intermediate states as targets for drug design</article-title>
        <source>Nat Commun.</source>
        <year>2014</year>
        <volume>5</volume>
        <fpage>3397</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms4397</pub-id>
        <pub-id pub-id-type="pmid">24584478</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Foda</surname>
            <given-names>ZH</given-names>
          </name>
          <name>
            <surname>Seeliger</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Kinase inhibitors: an allosteric add-on</article-title>
        <source>Nat Chem Biol</source>
        <year>2014</year>
        <volume>10</volume>
        <fpage>796</fpage>
        <lpage>797</lpage>
        <pub-id pub-id-type="doi">10.1038/nchembio.1630</pub-id>
        <pub-id pub-id-type="pmid">25195010</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sadowsky</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Burlingame</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Wolan</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>McClendon</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Jacobson</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Wells</surname>
            <given-names>JA</given-names>
          </name>
        </person-group>
        <article-title>Turning a protein kinase on or off from a single allosteric site via disulfide trapping</article-title>
        <source>Proc Natl Acad Sci USA</source>
        <year>2011</year>
        <volume>108</volume>
        <fpage>6056</fpage>
        <lpage>6061</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1102376108</pub-id>
        <pub-id pub-id-type="pmid">21430264</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tiwary</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Limongelli</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Salvalaglio</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Parrinello</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Kinetics of protein-ligand unbinding: predicting pathways, rates, and rate-limiting steps</article-title>
        <source>Proc Natl Acad Sci USA</source>
        <year>2015</year>
        <volume>112</volume>
        <fpage>E386</fpage>
        <lpage>E391</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1424461112</pub-id>
        <pub-id pub-id-type="pmid">25605901</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
